

Biosignal Limited

Suite 145, Level 1
National Innovation Centre
Australian Technology Park
EVELEIGH NSW 1430

Telephone +61 2 9209 4126
Facsimile +61 2 9209 4306

ACN 071 781 363
ABN 45 071 781 363

ASX/Media Announcement

University of Minnesota to test Biosignal anti-bacterials for dental applications

7 March 2007, Sydney: Biosignal Ltd (ASX: BOS) has signed a research agreement to enable the University of Minnesota to test biofilm inhibition of dental materials using Biosignal's anti-bacterial coatings.

The work is part of the collaboration with two US-based oral care experts Dr Gary Jernberg and Dr Richard Simonsen on a broad range of dental applications as announced on 8 January 2007. The School of Dentistry at the University of Minnesota is internationally recognised as a leader in oral microbiology and periodontal disease prevention.

Biosignal has supplied the anti-bacterial compounds for the testing that will proceed from March to June 07.

Biosignal will own intellectual property arising from the project. If the development is successful, Jernberg, Simonsen and Biosignal will seek to license the technology to leading dental product companies.

Inquiries: Michael Oredsson
02 9209 4106
m.oredsson@biosignal.com.au

Rudi Michelson
Monsoon Communications
0411 402 737
rudim@monsoon.com.au

About Biosignal and the anti-biofilm technology

Biosignal listed on the ASX in April 2004 to commercialise a novel anti-bacterial technology. The first application is reducing risks of infection from contact lenses.

Biosignal's anti-biofilm technology is based on a discovery that the eastern Australian seaweed *Delisea pulchra* produces natural furanones that disable bacteria's ability to colonise. The fundamental problem with existing anti-bacterials, including antibiotics, is their tendency to generate bacterial resistance. Bacteria rapidly produce resistant strains when faced with strong selective pressure by killing agents or growth-inhibitory agents. Furanones lull bacteria to inaction and appear to avoid the problem of bacterial resistance.

Biosignal produces synthetic compounds effective on inanimate surfaces such as pipes, membranes and medical devices; and animate surfaces such as lungs, skin and teeth.

About Jernberg and Simonsen

Dr Gary Jernberg is a dentist based in Minnesota. He has developed a number of patented technologies. One of these is a periodontal drug delivery system that has been successfully licensed to a major pharmaceutical company and is generating significant revenues.

Dr Richard Simonsen is world-renowned as an expert in conservative esthetic dentistry having pioneered a number of developments including the preventive resin restoration, dental sealants and etched porcelain restorations. Dr Simonsen is the Dean of the Midwestern University College of Dentistry. He is the former Associate Dean for Preclinical Affairs and Research at the Arizona School of Dentistry & Oral Health. Dr Simonsen wrote a textbook on clinical applications of the acid-etch technique in 1977. He has been awarded a Lifetime Achievement Award from the World Congress of Minimally Invasive Dentistry and received the 1999 Distinguished Service Award from the American Society of Dentistry for Children.